<DOC>
	<DOCNO>NCT00062010</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel , work different way stop tumor cell divide stop grow die . Some tumor become resistant chemotherapy drug . Giving interferon alfa isotretinoin together paclitaxel may reduce resistance drug allow tumor cell kill . PURPOSE : This phase II trial study well give interferon alfa isotretinoin together paclitaxel work treat patient recurrent small cell lung cancer .</brief_summary>
	<brief_title>Interferon Alfa , Isotretinoin , Paclitaxel Treating Patients With Recurrent Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine frequency duration response patient recurrent small cell lung cancer treat interferon alfa , isotretinoin , paclitaxel . - Determine toxic effect regimen patient . - Determine duration survival patient treat regimen . - Correlate level bcl-2 peripheral blood monocyte response survival patient treat regimen . OUTLINE : This multicenter study . Patients receive interferon alfa subcutaneously oral isotretinoin day 1 2 paclitaxel IV 1 hour day 2 week 1-6 . Courses repeat every 8 week absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month 1 year . PROJECTED ACCRUAL : A total 37-83 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>Inclusion Criteria Histologically cytologically confirm recurrent small cell lung cancer ( SCLC ) clinically confirm measurable disease Age 18 ECOG Performance status 03 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin great 1.5 mg/dL AST great 2 time upper limit normal ( ULN ) Creatinine great 1.5 mg/dL Triglycerides great 1.5 time ULN Patients must prior chemotherapy treatment SCLC , toxicity must resolve less equal grade 1 Women childbearing potential sexually active male strongly encourage use accept effective method contraception . Exclusion Criteria History another neoplasm SCLC except nonmetastatic , nonmelanoma skin cancer , carcinoma situ cervix , cancer cure surgery small field radiotherapy least 5 year registration Pregnant nursing , negative pregnancy test within 2 week prior registration Severe depression require medication Use follow drug within 4 week prior registration : carbamazepine , ethanol , tetracycline , doxycycline , minocycline , topical acne product contain RetinA , vitamin A , cisplatin , ketoconazole , phenytoin antiepileptic drug Use GMCSF GCSF within 4 week prior registration Prior paclitaxel interferon therapy Radiation therapy within 60 day prior registration Chemotherapy within 60 day prior registration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>recurrent small cell lung cancer</keyword>
</DOC>